0000000000243064

AUTHOR

Jan Budczies

showing 5 related works from this author

The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients.

2021

ABSTRACT Background and aims Due to the high load of immunogenic frameshift neoantigens, tumors arising in individuals with Lynch syndrome (LS), the most common inherited colorectal cancer (CRC) syndrome, are characterized by a pronounced immune infiltration. However, the immune status of normal colorectal mucosa in LS is not well characterized. We assessed the immune infiltrate in tumor-distant normal colorectal mucosa from LS CRC patients, sporadic microsatellite-unstable (MSI) and microsatellite-stable (MSS) CRC patients, and cancer-free LS carriers. Methods CD3-positive, FOXP3-positive and CD8-positive T cells were quantified in 219, 233 and 201 formalin-fixed paraffin-embedded (FFPE) n…

MaleCD3 ComplexColorectal cancerT-LymphocytesCD8-Positive T-LymphocytesT-Lymphocytes Regulatory0302 clinical medicineIntestinal MucosaMismatch Repair Endonuclease PMS2Aged 80 and over0303 health sciencesbiologyGastroenterologyFOXP3Forkhead Transcription FactorsMiddle AgedLynch syndrome3. Good healthDNA-Binding Proteinsmedicine.anatomical_structureMutS Homolog 2 Protein030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityMutL Protein Homolog 1AdultHeterozygoteColonT cellCD303 medical and health sciencesYoung AdultImmune systemmedicineHumansLymphocyte Count030304 developmental biologyAgedHepatologybusiness.industryCarcinomaRectumCancerMicrosatellite instabilitymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisCancer researchbiology.proteinbusinessTranscriptomeGastroenterology
researchProduct

RSPO2 gene rearrangement – a new cancer driver in the liver

2019

business.industryCancer researchMedicineCancerbusinessmedicine.diseaseRSPO2 Gene35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber
researchProduct

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma

2021

BACKGROUND: Targeted genetic profiling of tissue samples is paramount to detect druggable genetic aberrations in patients with non-squamous non-small cell lung cancer (NSCLC). Accurate upfront estimation of tumor cell content (TCC) is a crucial pre-analytical step for reliable testing and to avoid false-negative results. As of now, TCC is usually estimated on hematoxylin-eosin (H&E) stained tissue sections by a pathologist, a methodology that may be prone to substantial intra- and interobserver variability. Here we the investigate suitability of digital pathology for TCC estimation in a clinical setting by evaluating the concordance between semi-automatic and conventional TCC quantification…

0301 basic medicineOncologymedicine.medical_specialtyConcordanceTumor cellsurologic and male genital diseases03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerneoplasmsLungbusiness.industryMolecular pathologyDigital pathologymedicine.diseasefemale genital diseases and pregnancy complicationsddc:030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisAdenocarcinomaOriginal ArticleSemi automaticbusiness
researchProduct

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

2013

The validated EndoPredict assay is a novel tool to predict the risk of metastases of patients with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy alone. It has been designed to integrate genomic and clinical information and includes clinico-pathological factors such as tumor size and nodal status. The test is feasible in a decentral setting in molecular pathology laboratories. In this project, we investigated the performance of this test in clinical practice, and performed a retrospective evaluation of its impact on treatment decisions in breast cancer. During one year, EndoPredict assays from 167 patients could be successfully performed. For retrospe…

OncologyNon-Clinical Medicinemedicine.medical_treatmentCancer Treatmentlcsh:MedicineEstrogen receptorBioinformaticsMetastasisSurveys and QuestionnairesPathologylcsh:ScienceMultidisciplinaryMolecular pathologyCancer Risk FactorsHormonal TherapyObstetrics and GynecologyEndocrine TherapyMiddle AgedOncologyReceptors EstrogenCohortMedicineFemaleRisk assessmentMolecular PathologyResearch ArticleAdultmedicine.medical_specialtyAntineoplastic Agents HormonalGenetic Causes of CancerClinical Decision-MakingBreast NeoplasmsRisk AssessmentBreast cancerDiagnostic MedicineInternal medicineBreast CancermedicineHumansAgedRetrospective StudiesChemotherapyHealth Care Policybusiness.industryGene Expression Profilinglcsh:RHealth Risk AnalysisRetrospective cohort studyChemotherapy and Drug Treatmentmedicine.diseaselcsh:QbusinessGeneral PathologyPLoS ONE
researchProduct

RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours

2019

ObjectiveWe aimed at the identification of genetic alterations that may functionally substitute for CTNNB1 mutation in ß-catenin-activated hepatocellular adenomas (HCAs) and hepatocellular carcinoma (HCC).DesignLarge cohorts of HCA (n=185) and HCC (n=468) were classified using immunohistochemistry. The mutational status of the CTNNB1 gene was determined in ß-catenin-activated HCA (b-HCA) and HCC with at least moderate nuclear CTNNB1 accumulation. Ultra-deep sequencing was used to characterise CTNNB1wild-type and ß-catenin-activated HCA and HCC. Expression profiling of HCA subtypes was performed.ResultsA roof plate-specific spondin 2 (RSPO2) gene rearrangement resulting from a 46.4 kb microd…

Gene expression profilingGastroenterologyCancer researchWnt signaling pathwayTelomerase reverse transcriptaseGene rearrangementHCCSBiologyRSPO2Malignant transformationRSPO2 GeneGut
researchProduct